Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
EX-527, SEN0014196
print preview
bookmark
share with colleague
General Information
Company
Elixir Pharmaceuticals Inc.
Description
Oral, sirtuin 1 (SIRT1) inhibitor
Molecular Target
Sirtuin 1 (SIRT1)
Mechanism of Action
Sirtuin 1 (SIRT1) inhibitor
Latest Stage of Development
Phase I
Indication
Huntington's disease (HD)
Partner
Siena Biotech S.p.A.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy